We are live on
!
Find out more
CIA
Capital Impact Advisors Portfolio holdings
AUM
$247M
1-Year Est. Return
31.15%
This Fund
S&P 500
This Quarter
Est. Return
+10.7%
1 Year Est. Return
+31.15%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$286M
AUM Growth
-$122M
(-30%)
Cap. Flow
-$144M
Cap. Flow
% of AUM
-50.52%
Top 10 Holdings %
Top 10 Hldgs %
24.12%
Holding
143
New
41
Increased
10
Reduced
49
Closed
34
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Omnicom Group
OMC
|
+$8.21M |
| 2 |
Service Corp International
SCI
|
+$7.9M |
| 3 |
CLLS
Cellectis
CLLS
|
+$6.83M |
| 4 |
SF
Stifel
SF
|
+$6.38M |
| 5 |
Advance Auto Parts
AAP
|
+$6.34M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intellia Therapeutics
NTLA
|
+$14.5M |
| 2 |
Twist Bioscience
TWST
|
+$10.6M |
| 3 |
NVTA
Invitae Corporation
NVTA
|
+$9.84M |
| 4 |
Veracyte
VCYT
|
+$8.46M |
| 5 |
EXAS
Exact Sciences
EXAS
|
+$8.24M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.23% |
| 2 | Technology | 20.11% |
| 3 | Consumer Discretionary | 16.12% |
| 4 | Financials | 12.25% |
| 5 | Communication Services | 9.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Editas Medicine
EDIT
$396M
| $377K | 0.13% |
8,965
-121,035
| -93% | -$6.9M |
|
|
102
Intellia Therapeutics
NTLA
$1.49B
| $359K | 0.13% |
4,468
-215,532
| -98% | -$14.5M |
|
103
SS&C Technologies
SSNC
$18.1B
| $303K | 0.11% |
+4,341
| New | +$293K |
|
104
MongoDB
MDB
$27.1B
| $200K | 0.07% |
+749
| New | +$265K |
|
105
Impinj
PI
$4.62B
| $188K | 0.07% |
3,301
-47,015
| -93% | -$2.77M |
|
106
Ultragenyx Pharmaceutical
RARE
$2.45B
| $179K | 0.06% |
1,572
-24,010
| -94% | -$3.27M |
|
107
Phreesia
PHR
$663M
| $141K | 0.05% |
2,703
-41,297
| -94% | -$2.6M |
|
108
Castle Biosciences
CSTL
$855M
| $139K | 0.05% |
2,031
-22,969
| -92% | -$1.73M |
|
109
Mistras Group
MG
$484M
| $65K | 0.02% |
+5,719
| New | +$50.6K |
|
110
Allogene Therapeutics
ALLO
$649M
| – | – |
-41,800
| Closed | -$1.05M |
|
111
Arcturus Therapeutics
ARCT
$164M
| – | – |
-155,000
| Closed | -$6.72M |
|
112
Arrowhead Research
ARWR
$11.9B
| – | – |
-88,183
| Closed | -$6.77M |
|
113
Beam Therapeutics
BEAM
$2.63B
| – | – |
-25,000
| Closed | -$2.04M |
|
114
Datadog
DDOG
$95.4B
| – | – |
-44,000
| Closed | -$4.33M |
|
115
Danaher
DHR
$137B
| – | – |
-11,280
| Closed | -$2.22M |
|
|
DOYU
116
DouYu International Holdings
DOYU
$139M
| – | – |
-15,000
| Closed | -$1.66M |
|
117
Fate Therapeutics
FATE
$286M
| – | – |
-32,000
| Closed | -$2.91M |
|
118
Fastly Inc
FSLY
$3.55B
| – | – |
-50,000
| Closed | -$4.37M |
|
119
GeoPark
GPRK
$633M
| – | – |
-13,042
| Closed | -$4.68M |
|
120
Ionis Pharmaceuticals
IONS
$8.6B
| – | – |
-63,707
| Closed | -$3.6M |
|
121
Kura Oncology
KURA
$800M
| – | – |
-62,331
| Closed | -$2.04M |
|
122
Li Auto
LI
$13.4B
| – | – |
-40,000
| Closed | -$1.15M |
|
123
Netflix
NFLX
$299B
| – | – |
-103,860
| Closed | -$5.62M |
|
124
Natera
NTRA
$38.3B
| – | – |
-50,000
| Closed | -$4.98M |
|
125
Okta
OKTA
$24.7B
| – | – |
-15,000
| Closed | -$3.81M |
|
Similar funds
AI
AB
PWS
BFM
IFPG
SCM
GWS
MC
Capital Impact Advisors's Q1 2021 Portfolio in Review
As of Q1 2021, Capital Impact Advisors held 143 positions worth $286M, down 30% from $407M the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Capital Impact Advisors withdrew a net $144M in Q1 2021, closing 34 positions and reducing 49 holdings. Its most notable exit was Personalis, an estimated $7.88M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 25% of assets, down from 45% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Capital Impact Advisors opened a new position in Omnicom Group worth $8.82M.
- Capital Impact Advisors's largest Q1 2021 buy was Omnicom Group: 118,943 shares worth $8.82M.
- Capital Impact Advisors added most to Cellectis in Q1 2021, an estimated $6.83M increase.
- Capital Impact Advisors's biggest Q1 2021 reduction was Intellia Therapeutics, cutting an estimated $14.5M.
- Capital Impact Advisors fully exited Personalis in Q1 2021, selling an estimated $7.88M.
- Capital Impact Advisors's ten largest holdings make up 24% of its $286M portfolio in Q1 2021.
- Capital Impact Advisors opened 41 new positions and closed 34 in Q1 2021.
- Capital Impact Advisors's portfolio value fell 30% quarter-over-quarter to $286M.
Based on Capital Impact Advisors's 13F filing for Q1 2021, filed 18 May 2021.